Morgan Stanley has upgraded Cencora (COR) from Equal Weight to Overweight, raising the price target to $400 from $361. This decision reflects Cencora's growing influence in the specialty sector, bolstered by its major acquisition of OneOncology. The firm is also considering strategic options for its non-core assets, a move that could enhance business efficiency and provide value, according to Morgan Stanley's analysis.
Looking ahead, the company is expected to benefit from an international recovery anticipated in 2026, with support from World Courier activities. These strategic decisions and market conditions position Cencora favorably for future growth and opportunities.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.